[Hopeful]

gdpawel,

I had the Oncotype test and regret having done so, because all it did for me was raise anxiety levels. I have done extensive reading and research since my dx, and I have reservations as to how sensitive that test is for Her2+ patients - the formula for risk calculation that the test uses weighs that particular gene very heavily. As research into Her2+ bc continues, studies show that not all Her2+ bc is equal, but the current version of Oncotype treats them that way. Thus far, all of the validation studies have been done in retrospective cases. I will be most interested in seeing the results of the TailorX trial, limited to Her2- patients, to see how the results stack up against the validation studies.

The fact that researchers are developing tests of any type to try and distinguish characteristics of individual cancers that will better direct treatment is a very positive development. Like every new techonology, it requires refinement, which will come the more they are used.

Hopeful